ZYDUSLIFE
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
India's Zydus Lifesciences hits six-month peak on buyback plan
** Shares of Zydus Lifesciences ZYDU.NS rise 5% to a more than six-month high at 986 rupees
** The Indian drugmaker to consider equity share buyback proposal on May 19, 2026
** Company's unit buys U.S. specialty drugmaker Assertio for $166.4 million
** Average rating of 27 analysts covering the stock is "hold" and median PT is 975 rupees - data compiled by LSEG
** YTD, ZYDU stock up 7.9%
(Reporting by Brijesh Patel in Bengaluru)
(([email protected]; Ph no. +91 9590227221;))
** Shares of Zydus Lifesciences ZYDU.NS rise 5% to a more than six-month high at 986 rupees
** The Indian drugmaker to consider equity share buyback proposal on May 19, 2026
** Company's unit buys U.S. specialty drugmaker Assertio for $166.4 million
** Average rating of 27 analysts covering the stock is "hold" and median PT is 975 rupees - data compiled by LSEG
** YTD, ZYDU stock up 7.9%
(Reporting by Brijesh Patel in Bengaluru)
(([email protected]; Ph no. +91 9590227221;))
Zydus Lifesciences To Buy Assertio For $166.4 Million
May 13 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - UNIT TO BUY ALL OUTSTANDING SHARES OF ASSERTIO HOLDINGS
ZYDUS LIFESCIENCES - TO BUY ASSERTIO FOR $23.50 PER SHARE, TOTAL $166.4 MILLION
Source text: ID:nBSE1CYQtb
Further company coverage: ZYDU.NS
(([email protected];;))
May 13 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - UNIT TO BUY ALL OUTSTANDING SHARES OF ASSERTIO HOLDINGS
ZYDUS LIFESCIENCES - TO BUY ASSERTIO FOR $23.50 PER SHARE, TOTAL $166.4 MILLION
Source text: ID:nBSE1CYQtb
Further company coverage: ZYDU.NS
(([email protected];;))
Zydus Lifesciences Says USFDA Inspection Concludes At Zydus' Biologics Injectable Plant, Ahmedabad
May 6 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - USFDA INSPECTION CONCLUDES AT ZYDUS' BIOLOGICS INJECTABLE PLANT, AHMEDABAD
ZYDUS LIFESCIENCES - INSPECTION CLOSED WITH SEVEN OBSERVATIONS; NO DATA INTEGRITY RELATED OBSERVATIONS
Source text: ID:nNSE4KV2h8
Further company coverage: ZYDU.NS
(([email protected];))
May 6 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - USFDA INSPECTION CONCLUDES AT ZYDUS' BIOLOGICS INJECTABLE PLANT, AHMEDABAD
ZYDUS LIFESCIENCES - INSPECTION CLOSED WITH SEVEN OBSERVATIONS; NO DATA INTEGRITY RELATED OBSERVATIONS
Source text: ID:nNSE4KV2h8
Further company coverage: ZYDU.NS
(([email protected];))
Zydus Lifesciences Says Unit Receives Tax Demand And Penalty Of 9 Million Rupees Each
May 5 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - UNIT RECEIVES TAX DEMAND AND PENALTY OF 9 MILLION RUPEES EACH
Source text: ID:nNSEcQbgX
Further company coverage: ZYDU.NS
(([email protected];))
May 5 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - UNIT RECEIVES TAX DEMAND AND PENALTY OF 9 MILLION RUPEES EACH
Source text: ID:nNSEcQbgX
Further company coverage: ZYDU.NS
(([email protected];))
Zydus Lifesciences Unit Buys 100% Of Aptitude Orthopedie, France
May 1 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
UNIT BUYS 100% OF APTITUDE ORTHOPEDIE, FRANCE
ACQUISITION FOR 360,000 EUROS
Source text: ID:nNSE92fBJq
Further company coverage: ZYDU.NS
(([email protected];))
May 1 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
UNIT BUYS 100% OF APTITUDE ORTHOPEDIE, FRANCE
ACQUISITION FOR 360,000 EUROS
Source text: ID:nNSE92fBJq
Further company coverage: ZYDU.NS
(([email protected];))
Zydus Lifesciences Says Subsidiary Has Been Incorporated In Name Of Zara Merger Sub Inc
April 30 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - SUBSIDIARY HAS BEEN INCORPORATED IN NAME OF ZARA MERGER SUB INC
Source text: ID:nnAZN4STMQM
Further company coverage: ZYDU.NS
(([email protected];))
April 30 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - SUBSIDIARY HAS BEEN INCORPORATED IN NAME OF ZARA MERGER SUB INC
Source text: ID:nnAZN4STMQM
Further company coverage: ZYDU.NS
(([email protected];))
Algorae Pharmaceuticals And Zydus Enter Exclusive Commercial Agreement
April 28 (Reuters) - Algorae Pharmaceuticals Ltd 1AI.AX:
ALGORAE AND ZYDUS ENTER EXCLUSIVE COMMERCIAL AGREEMENT
AGREEMENT FOR 10 PRODUCTS WITH ZYDUS LIFESCIENCES FOR AUSTRALIAN AND NEW ZEALAND MARKETS
Further company coverage: 1AI.AX
(([email protected];))
April 28 (Reuters) - Algorae Pharmaceuticals Ltd 1AI.AX:
ALGORAE AND ZYDUS ENTER EXCLUSIVE COMMERCIAL AGREEMENT
AGREEMENT FOR 10 PRODUCTS WITH ZYDUS LIFESCIENCES FOR AUSTRALIAN AND NEW ZEALAND MARKETS
Further company coverage: 1AI.AX
(([email protected];))
Zydus Lifesciences Receives EIR For Oncology Injectable Manufacturing Facility In SEZ1, Ahmedabad
April 16 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES- ZYDUS RECEIVES EIR FOR ONCOLOGY INJECTABLE MANUFACTURING FACILITY IN SEZ1, AHMEDABAD
Source text: ID:nnAZN4SR4T1
Further company coverage: ZYDU.NS
(([email protected];))
April 16 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES- ZYDUS RECEIVES EIR FOR ONCOLOGY INJECTABLE MANUFACTURING FACILITY IN SEZ1, AHMEDABAD
Source text: ID:nnAZN4SR4T1
Further company coverage: ZYDU.NS
(([email protected];))
FOCUS-Patients scramble to find estrogen patches as shortage worsens after US FDA champions use
Easing safety warnings, shift in sentiment toward HRT trigger sharp increases in use
Patients report pharmacy-hopping and dose changes
Manufacturers say complex production limit rapid scale-up
By Mrinalika Roy and Sriparna Roy
April 9 (Reuters) - A surge in demand since last year for estrogen patches to ease menopause symptoms has strained supplies and led to shortages, sparking a scramble for medicines that industry sources say could last up to three years.
More than 1 million U.S. women begin menopause each year. Over the past two years they have increasingly sought out estrogen patches to treat mood swings, hot flashes and sleep disturbances. Social media in particular has been a forum for changing views on the medicines' safety and benefits.
The U.S. FDA began publicly extolling hormone replacement therapy as "lifesaving" last July, and in November it removed a longstanding safety warning from the therapies. The change in the Food and Drug Administration's stance was followed by a 26% jump in patch use through February, according to data from health data and analytics company Truveta.
"When the FDA removed the safety warning in November, it created unprecedented demand that cannot fully be met at present," said a spokesperson for Swiss generics manufacturer Sandoz SDZ.S, which has shipped additional supplies to the U.S. to help ease shortages.
The patches are a type of hormone replacement therapy that delivers estrogen directly through the skin into the bloodstream.
"For 20 years, less than 5% of women took hormone therapy. Now those numbers are growing... and scaling up production of medications is not as easy as it might seem," said Dr. Gillian Goddard, adjunct assistant professor at the NYU Grossman School of Medicine.
While the FDA has not designated the patches as being in shortage, women are pharmacy-hopping in search of them, reducing or switching dosages and changing brands or types of therapy, according to interviews with six patients, three telehealth companies, and six industry experts.
Abruptly stopping use can restart symptoms, while switching brands may bring new side effects, doctors said.
SEARCHING FOR SUPPLY
Amy Satterlund, 50, a product manager from Fort Pierce, Colorado, has been using the estrogen patch for about 18 months, but has recently struggled to find it.
She said she has had to plan for shortages at CVS pharmacies and long waits at online pharmacy Cost Plus Drugs.
"I do get nervous if I were unable to get my prescription refilled, that side effects or that the symptoms of perimenopause would come back," Satterlund said.
A CVS Health CVS.N spokesperson said manufacturers have been unable to deliver sufficient quantities in recent weeks.
A Cost Plus spokesperson said it has added supply to keep up with exploding demand, but hasn't heard from its suppliers on shortages lasting for an extended period of time.
Andrew Nixon, a spokesman for the U.S. Health and Human Services Department, which oversees the FDA, said the agency is coordinating with companies to support efforts to boost the supply of patches.
CHANGING GUIDANCE, RISING DEMAND
FDA Commissioner Marty Makary last July turned the tables on previous cautions against HRT use. In interviews and postings, he said women had been advised against the treatments due to cancer risks, but that the scientific evidence has changed.
The 2002 Women's Health Initiative study had linked hormone therapy to increased risks for some cancers, dementia, heart attacks and stroke. Now, the American College of Obstetricians and Gynecologists on its website notes risks and benefits to the various types of HRT and advises patients who use them to talk with their doctor every year about whether to continue.
Using its electronic health record database covering more than 130 million patients in all 50 states, Truveta found use of most forms of HRT has climbed in recent years, with the sharpest increase a 184% jump in estrogen patches since 2023. Vaginal cream HRT use rose 122% over the same period.
By February 2026, about 5 out of 100 women aged 45-54 had been prescribed estrogen-based HRT, roughly doubling since 2023, based on an analysis of women who had received any medical prescription during that period.
Telehealth platform HRT Club, which helps patients access hormone therapies and physicians, said patch sales had risen 150% since the FDA's November actions.
MANUFACTURING BARRIERS
Estrogen patches are generic medicines with low profit margins, providing manufacturers few incentives to invest quickly in new production lines or facilities that can take years to build.
Long-term contracts for supplies can also hinder manufacturers from quickly adjusting to demand changes, industry sources and doctors said.
Major makers of the patches, including Amneal AMRX.O, Zydus ZYDU.NS, Sandoz, Noven, and Viatris VTRS.O, all have some doses in shortage, according to the American Society of Health-System Pharmacists.
Amneal and Viatris said they were trying to boost patch supply to meet demand. Zydus and Noven did not respond to a request for comment.
Dr. Mary Rosser, an Ob-Gyn and director of Integrated Women's Health at Columbia University, said the FDA does have ways to mitigate shortages. These could include requiring manufacturers to have more diverse and back-up supply chains, and mandating minimum inventories and proactive inventory monitoring systems, she said.
The FDA declined to comment on such options.
"People have waited a long time to make a decision... about whether they want to use hormones," Rosser said. "Then they make the decision and then they can't get them."
U.S. Estrogen Patch Sales Have Surged In Recent Years https://reut.rs/4rByhpk
Hormone Replacement Therapy Dispenses per 1000 Women By Type https://reut.rs/3Q064LC
Hormone Replacement Therapy Prescriptions Per 1000 Women https://reut.rs/41Tdjrn
(Reporting by Mrinalika Roy, Mariam Sunny, and Sriparna Roy in Bengaluru; Editing by Caroline Humer and Bill Berkrot)
(([email protected];))
Easing safety warnings, shift in sentiment toward HRT trigger sharp increases in use
Patients report pharmacy-hopping and dose changes
Manufacturers say complex production limit rapid scale-up
By Mrinalika Roy and Sriparna Roy
April 9 (Reuters) - A surge in demand since last year for estrogen patches to ease menopause symptoms has strained supplies and led to shortages, sparking a scramble for medicines that industry sources say could last up to three years.
More than 1 million U.S. women begin menopause each year. Over the past two years they have increasingly sought out estrogen patches to treat mood swings, hot flashes and sleep disturbances. Social media in particular has been a forum for changing views on the medicines' safety and benefits.
The U.S. FDA began publicly extolling hormone replacement therapy as "lifesaving" last July, and in November it removed a longstanding safety warning from the therapies. The change in the Food and Drug Administration's stance was followed by a 26% jump in patch use through February, according to data from health data and analytics company Truveta.
"When the FDA removed the safety warning in November, it created unprecedented demand that cannot fully be met at present," said a spokesperson for Swiss generics manufacturer Sandoz SDZ.S, which has shipped additional supplies to the U.S. to help ease shortages.
The patches are a type of hormone replacement therapy that delivers estrogen directly through the skin into the bloodstream.
"For 20 years, less than 5% of women took hormone therapy. Now those numbers are growing... and scaling up production of medications is not as easy as it might seem," said Dr. Gillian Goddard, adjunct assistant professor at the NYU Grossman School of Medicine.
While the FDA has not designated the patches as being in shortage, women are pharmacy-hopping in search of them, reducing or switching dosages and changing brands or types of therapy, according to interviews with six patients, three telehealth companies, and six industry experts.
Abruptly stopping use can restart symptoms, while switching brands may bring new side effects, doctors said.
SEARCHING FOR SUPPLY
Amy Satterlund, 50, a product manager from Fort Pierce, Colorado, has been using the estrogen patch for about 18 months, but has recently struggled to find it.
She said she has had to plan for shortages at CVS pharmacies and long waits at online pharmacy Cost Plus Drugs.
"I do get nervous if I were unable to get my prescription refilled, that side effects or that the symptoms of perimenopause would come back," Satterlund said.
A CVS Health CVS.N spokesperson said manufacturers have been unable to deliver sufficient quantities in recent weeks.
A Cost Plus spokesperson said it has added supply to keep up with exploding demand, but hasn't heard from its suppliers on shortages lasting for an extended period of time.
Andrew Nixon, a spokesman for the U.S. Health and Human Services Department, which oversees the FDA, said the agency is coordinating with companies to support efforts to boost the supply of patches.
CHANGING GUIDANCE, RISING DEMAND
FDA Commissioner Marty Makary last July turned the tables on previous cautions against HRT use. In interviews and postings, he said women had been advised against the treatments due to cancer risks, but that the scientific evidence has changed.
The 2002 Women's Health Initiative study had linked hormone therapy to increased risks for some cancers, dementia, heart attacks and stroke. Now, the American College of Obstetricians and Gynecologists on its website notes risks and benefits to the various types of HRT and advises patients who use them to talk with their doctor every year about whether to continue.
Using its electronic health record database covering more than 130 million patients in all 50 states, Truveta found use of most forms of HRT has climbed in recent years, with the sharpest increase a 184% jump in estrogen patches since 2023. Vaginal cream HRT use rose 122% over the same period.
By February 2026, about 5 out of 100 women aged 45-54 had been prescribed estrogen-based HRT, roughly doubling since 2023, based on an analysis of women who had received any medical prescription during that period.
Telehealth platform HRT Club, which helps patients access hormone therapies and physicians, said patch sales had risen 150% since the FDA's November actions.
MANUFACTURING BARRIERS
Estrogen patches are generic medicines with low profit margins, providing manufacturers few incentives to invest quickly in new production lines or facilities that can take years to build.
Long-term contracts for supplies can also hinder manufacturers from quickly adjusting to demand changes, industry sources and doctors said.
Major makers of the patches, including Amneal AMRX.O, Zydus ZYDU.NS, Sandoz, Noven, and Viatris VTRS.O, all have some doses in shortage, according to the American Society of Health-System Pharmacists.
Amneal and Viatris said they were trying to boost patch supply to meet demand. Zydus and Noven did not respond to a request for comment.
Dr. Mary Rosser, an Ob-Gyn and director of Integrated Women's Health at Columbia University, said the FDA does have ways to mitigate shortages. These could include requiring manufacturers to have more diverse and back-up supply chains, and mandating minimum inventories and proactive inventory monitoring systems, she said.
The FDA declined to comment on such options.
"People have waited a long time to make a decision... about whether they want to use hormones," Rosser said. "Then they make the decision and then they can't get them."
U.S. Estrogen Patch Sales Have Surged In Recent Years https://reut.rs/4rByhpk
Hormone Replacement Therapy Dispenses per 1000 Women By Type https://reut.rs/3Q064LC
Hormone Replacement Therapy Prescriptions Per 1000 Women https://reut.rs/41Tdjrn
(Reporting by Mrinalika Roy, Mariam Sunny, and Sriparna Roy in Bengaluru; Editing by Caroline Humer and Bill Berkrot)
(([email protected];))
Zydus Lifesciences Receives Final USFDA Approval For Dapagliflozin Tablets
April 8 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES FINAL USFDA APPROVAL FOR DAPAGLIFLOZIN TABLETS
Source text: ID:nNSE7lyqfm
Further company coverage: ZYDU.NS
(([email protected];;))
April 8 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES FINAL USFDA APPROVAL FOR DAPAGLIFLOZIN TABLETS
Source text: ID:nNSE7lyqfm
Further company coverage: ZYDU.NS
(([email protected];;))
Zydus Lifesciences Says Tax Demand Of 41.77 Million Rupees Dropped
April 6 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - TAX DEMAND OF 41.77 MILLION RUPEES DROPPED
Source text: ID:nNSE7S2XC2
Further company coverage: ZYDU.NS
(([email protected];))
April 6 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - TAX DEMAND OF 41.77 MILLION RUPEES DROPPED
Source text: ID:nNSE7S2XC2
Further company coverage: ZYDU.NS
(([email protected];))
India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation
Indian clinics market pre-wedding weight-loss packages with Mounjaro and Wegovy
India obesity drugs market seen reaching $860.34 million by 2030
Drug regulator raises concerns over potential misuse as local drugmakers launch cheaper weight-loss drugs
By Rishika Sadam
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.
New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers.
In a social media video, Klarity offers "guided nutrition, Mounjaro and smart workouts" to prepare brides to walk down the aisle. The clinic did not respond to a request for comment.
Eight doctors interviewed by Reuters said they have been fielding inquiries from brides, and some grooms, about taking weight-loss drugs before taking their vows. Many asked for Eli Lilly's LLY.N Mounjaro, the first GLP-1 medication to enter India's market for both diabetes and weight loss. It has become more sought after than Novo Nordisk's NOVOb.CO rival Wegovy, the doctors said.
"Over the last few months, over 20% of the queries we've received for obesity injections are from to-be brides, who also openly give us a timeline on how soon they are getting married," said Rajat Goel, a bariatric surgeon at Hindivine Healthcare in New Delhi.
He said he prescribed the drugs only if patients were medically eligible, not for cosmetic use.
TRADITION AND SOCIETAL PRESSURE
Weddings in India are grand affairs for families that can afford them, with culture and tradition exerting a strong influence. Many marriages continue to be arranged by families, often bringing expectations around physical appearance and financial status.
Aditi, a 26-year-old finance worker from Mumbai, consulted a doctor in November for a weight-loss prescription after exercise and diet failed to get the desired results.
"When I see the result, I feel happy,” Aditi said about losing 10 kilograms (22 pounds) on Mounjaro before her February wedding. "If I am not happy, I don't feel confident. I did not want to feel that way at the time of the wedding."
She is one of the half a dozen brides, and one groom, who spoke to Reuters about pre-wedding use of weight-loss drugs, but asked not to use their family names due to social stigmas. They cited societal pressure to look a "certain way" at their wedding and most had discontinued the injections soon after.
Novo and Lilly launched their obesity drugs in India last year. The market is forecast to reach 80 billion rupees ($851.79 million) by 2030. Mounjaro sales doubled in the months after launch, making it the highest-selling drug in the world's most populous nation.
Indian drugmakers began selling cheaper versions of Novo's medicine last month after the patent on semaglutide, its active ingredient, expired, widening access.
The drugs are intended for adults classified as obese, or for those considered overweight with a weight-related medical condition such as diabetes, hypertension or sleep apnea.
"Mounjaro has been approved by regulators for specific medical indications and is intended to be used only under the supervision of a qualified healthcare professional," Lilly said in a statement.
The lowest Mounjaro injection pen dose sells for 13,125 rupees ($139.50) per month in India, while the highest dose costs 25,781 rupees.
Novo, which this week cut prices of Ozempic and Wegovy for the second time, is selling the lowest Wegovy dose for 5,660 rupees ($60.90) and the highest for 16,400 rupees a month.
Novo said it discourages any form of self-medication of semaglutide or deviation from the indicated use on label.
CHEAPER DRUGS, MISUSE CONCERNS
India could have more than 440 million overweight or obese people by 2050, one of the world's highest totals, according to The Lancet.
Akshitha, who got married in Hyderabad last year, said the drugs helped her shed 15 kg (33 pounds), taking her weight to 76 kg before the wedding. A family doctor had suggested she try the injections when she worried about her weight, she said.
"There's so much chaos before the wedding, with all the planning and preparation. I knew I would not get time to go to the gym and be on a diet. That's when these drugs looked like a better option," she said, adding she might consider using them again after a future pregnancy.
With local drugmakers flooding the market with cheaper weight-loss medicines, India's drugs regulator has raised concerns about misuse and intensified scrutiny of unauthorized sales and promotion.
"We understand the curiosity, but this cannot be a quick fix," said Dr. Swati Pradhan, founder of obesity and metabolic wellness clinic Live Light.
Pradhan said she prescribed the injections to only a few soon-to-be brides if they were medically eligible and showed signs of other medical issues, while insisting on lifestyle changes for sustainable results.
For 27-year-old Priya, a tech worker from Bengaluru, weight-loss drugs became a way to counter body-shaming from prospective grooms' families.
"I've had men and their families reject my proposal because of my weight. I was told I was fat," Priya told Reuters.
She initially used Novo's oral semaglutide, approved in India for diabetes, as an off-label treatment and lost more than 12 kg before switching to injectable Mounjaro.
Her search for a groom continues.
($1 = 94.0850 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad; Editing by Bill Berkrot)
(([email protected];))
Indian clinics market pre-wedding weight-loss packages with Mounjaro and Wegovy
India obesity drugs market seen reaching $860.34 million by 2030
Drug regulator raises concerns over potential misuse as local drugmakers launch cheaper weight-loss drugs
By Rishika Sadam
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.
New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers.
In a social media video, Klarity offers "guided nutrition, Mounjaro and smart workouts" to prepare brides to walk down the aisle. The clinic did not respond to a request for comment.
Eight doctors interviewed by Reuters said they have been fielding inquiries from brides, and some grooms, about taking weight-loss drugs before taking their vows. Many asked for Eli Lilly's LLY.N Mounjaro, the first GLP-1 medication to enter India's market for both diabetes and weight loss. It has become more sought after than Novo Nordisk's NOVOb.CO rival Wegovy, the doctors said.
"Over the last few months, over 20% of the queries we've received for obesity injections are from to-be brides, who also openly give us a timeline on how soon they are getting married," said Rajat Goel, a bariatric surgeon at Hindivine Healthcare in New Delhi.
He said he prescribed the drugs only if patients were medically eligible, not for cosmetic use.
TRADITION AND SOCIETAL PRESSURE
Weddings in India are grand affairs for families that can afford them, with culture and tradition exerting a strong influence. Many marriages continue to be arranged by families, often bringing expectations around physical appearance and financial status.
Aditi, a 26-year-old finance worker from Mumbai, consulted a doctor in November for a weight-loss prescription after exercise and diet failed to get the desired results.
"When I see the result, I feel happy,” Aditi said about losing 10 kilograms (22 pounds) on Mounjaro before her February wedding. "If I am not happy, I don't feel confident. I did not want to feel that way at the time of the wedding."
She is one of the half a dozen brides, and one groom, who spoke to Reuters about pre-wedding use of weight-loss drugs, but asked not to use their family names due to social stigmas. They cited societal pressure to look a "certain way" at their wedding and most had discontinued the injections soon after.
Novo and Lilly launched their obesity drugs in India last year. The market is forecast to reach 80 billion rupees ($851.79 million) by 2030. Mounjaro sales doubled in the months after launch, making it the highest-selling drug in the world's most populous nation.
Indian drugmakers began selling cheaper versions of Novo's medicine last month after the patent on semaglutide, its active ingredient, expired, widening access.
The drugs are intended for adults classified as obese, or for those considered overweight with a weight-related medical condition such as diabetes, hypertension or sleep apnea.
"Mounjaro has been approved by regulators for specific medical indications and is intended to be used only under the supervision of a qualified healthcare professional," Lilly said in a statement.
The lowest Mounjaro injection pen dose sells for 13,125 rupees ($139.50) per month in India, while the highest dose costs 25,781 rupees.
Novo, which this week cut prices of Ozempic and Wegovy for the second time, is selling the lowest Wegovy dose for 5,660 rupees ($60.90) and the highest for 16,400 rupees a month.
Novo said it discourages any form of self-medication of semaglutide or deviation from the indicated use on label.
CHEAPER DRUGS, MISUSE CONCERNS
India could have more than 440 million overweight or obese people by 2050, one of the world's highest totals, according to The Lancet.
Akshitha, who got married in Hyderabad last year, said the drugs helped her shed 15 kg (33 pounds), taking her weight to 76 kg before the wedding. A family doctor had suggested she try the injections when she worried about her weight, she said.
"There's so much chaos before the wedding, with all the planning and preparation. I knew I would not get time to go to the gym and be on a diet. That's when these drugs looked like a better option," she said, adding she might consider using them again after a future pregnancy.
With local drugmakers flooding the market with cheaper weight-loss medicines, India's drugs regulator has raised concerns about misuse and intensified scrutiny of unauthorized sales and promotion.
"We understand the curiosity, but this cannot be a quick fix," said Dr. Swati Pradhan, founder of obesity and metabolic wellness clinic Live Light.
Pradhan said she prescribed the injections to only a few soon-to-be brides if they were medically eligible and showed signs of other medical issues, while insisting on lifestyle changes for sustainable results.
For 27-year-old Priya, a tech worker from Bengaluru, weight-loss drugs became a way to counter body-shaming from prospective grooms' families.
"I've had men and their families reject my proposal because of my weight. I was told I was fat," Priya told Reuters.
She initially used Novo's oral semaglutide, approved in India for diabetes, as an off-label treatment and lost more than 12 kg before switching to injectable Mounjaro.
Her search for a groom continues.
($1 = 94.0850 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad; Editing by Bill Berkrot)
(([email protected];))
Zydus Lifesciences Receives Demand Order For FY 2019-20 To FY 2023-24
April 1 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES DEMAND ORDER FOR FY2019-20 TO FY2023-24
GETS TAX DEMAND ORDER WORTH 14.2 MILLION RUPEES
Source text: ID:nNSE86Nt5q
Further company coverage: ZYDU.NS
(([email protected];))
April 1 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES DEMAND ORDER FOR FY2019-20 TO FY2023-24
GETS TAX DEMAND ORDER WORTH 14.2 MILLION RUPEES
Source text: ID:nNSE86Nt5q
Further company coverage: ZYDU.NS
(([email protected];))
Novo Nordisk cuts Ozempic, Wegovy prices in India again to fight cheaper generics
Adds details, background, comments
By Rishika Sadam
March 31 (Reuters) - Novo Nordisk NOVOb.CO has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off competition from cheaper generics made by local drugmakers.
India's market for diabetes and weight-loss drugs is set for a shake-up after the Danish drugmaker's patent on semaglutide, the active component in Ozempic and Wegovy, expired on March 20.
At least half a dozen Indian drugmakers, including Dr Reddy's REDY.NS, Zydus ZYDU.NS and Sun Pharma SUN.NS, launched multiple brands of the blockbuster diabetes and weight-loss drugs, up to 70% cheaper than Novo's drugs in some cases.
Ozempic's and Wegovy's lowest doses of 0.25 mg in India will now be priced at 1,415 rupees ($15.04) for a weekly shot from 2,200 rupees and 2,712 rupees earlier, respectively, Novo Nordisk India said in a statement on Tuesday.
The average price reduction across doses is 23.8% for Ozempic and 27% for Wegovy, it said.
"We've heard from patients and doctors, and we're acting on that feedback," said Vikrant Shrotriya, managing director at Novo Nordisk India, adding that the drugs also offer cardiovascular benefits.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched its blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of its launch, according to data from Pharmarack, a research firm.
Novo's Ozempic is available in three dose strengths of 0.25 mg, 0.5 mg and 1 mg in India, while Wegovy has five dose strengths.
Ozempic's and Wegovy's 1 mg weekly shot is now priced at 2,275 rupees ($24.18) after price cuts of 18.5% and 34.2%, respectively. The company slashed Wegovy's 0.5 mg dose price by 41.5% to 2,025 rupees.
"..this price reduction reflects how innovation can become more accessible when market dynamics evolve," Venu Gopal Pareek, a bariatric surgeon said, adding that patients might choose Novo's drugs over generics given that it is an original molecule, and if the price difference is not beyond 15%.
Last year, Novo slashed Wegovy's price for the first time by up to 37% from its launch price, anticipating stiff competition from local drugmakers.
($1 = 93.9890 Indian rupees)
(Reporting by Rishika Sadam and Yagnoseni Das in Bengaluru; Editing by Devika Syamnath and Janane Venkatraman)
Adds details, background, comments
By Rishika Sadam
March 31 (Reuters) - Novo Nordisk NOVOb.CO has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off competition from cheaper generics made by local drugmakers.
India's market for diabetes and weight-loss drugs is set for a shake-up after the Danish drugmaker's patent on semaglutide, the active component in Ozempic and Wegovy, expired on March 20.
At least half a dozen Indian drugmakers, including Dr Reddy's REDY.NS, Zydus ZYDU.NS and Sun Pharma SUN.NS, launched multiple brands of the blockbuster diabetes and weight-loss drugs, up to 70% cheaper than Novo's drugs in some cases.
Ozempic's and Wegovy's lowest doses of 0.25 mg in India will now be priced at 1,415 rupees ($15.04) for a weekly shot from 2,200 rupees and 2,712 rupees earlier, respectively, Novo Nordisk India said in a statement on Tuesday.
The average price reduction across doses is 23.8% for Ozempic and 27% for Wegovy, it said.
"We've heard from patients and doctors, and we're acting on that feedback," said Vikrant Shrotriya, managing director at Novo Nordisk India, adding that the drugs also offer cardiovascular benefits.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched its blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of its launch, according to data from Pharmarack, a research firm.
Novo's Ozempic is available in three dose strengths of 0.25 mg, 0.5 mg and 1 mg in India, while Wegovy has five dose strengths.
Ozempic's and Wegovy's 1 mg weekly shot is now priced at 2,275 rupees ($24.18) after price cuts of 18.5% and 34.2%, respectively. The company slashed Wegovy's 0.5 mg dose price by 41.5% to 2,025 rupees.
"..this price reduction reflects how innovation can become more accessible when market dynamics evolve," Venu Gopal Pareek, a bariatric surgeon said, adding that patients might choose Novo's drugs over generics given that it is an original molecule, and if the price difference is not beyond 15%.
Last year, Novo slashed Wegovy's price for the first time by up to 37% from its launch price, anticipating stiff competition from local drugmakers.
($1 = 93.9890 Indian rupees)
(Reporting by Rishika Sadam and Yagnoseni Das in Bengaluru; Editing by Devika Syamnath and Janane Venkatraman)
Zydus Lifesciences Receives Tax Demand Penalty Of 32.8 Mln Rupees
March 25 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES TAX DEMAND PENALTY OF 32.8 MILLION RUPEES
Source text: ID:nNSE5c3vKr
Further company coverage: ZYDU.NS
(([email protected];;))
March 25 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES TAX DEMAND PENALTY OF 32.8 MILLION RUPEES
Source text: ID:nNSE5c3vKr
Further company coverage: ZYDU.NS
(([email protected];;))
India drug regulator tightens surveillance against unauthorised weight-loss drug sales
Adds background, details from statement
March 24 (Reuters) - India's drug regulator has tightened surveillance against the unauthorised sale and promotion of weight-loss drugs, the health ministry said on Tuesday, after local drugmakers launched cheaper generic versions of Ozempic and Wegovy over the weekend.
At least half a dozen Indian drugmakers, including Dr Reddy's REDY.NS, Zydus ZYDU.NS and Sun Pharma SUN.NS, launched multiple brands of the blockbuster diabetes and weight-loss drugs, up to 70% cheaper than Novo Nordisk's drugs in some cases, after the patent for semaglutide expired last week.
Semaglutide is the active component in Ozempic and Wegovy.
The patent expiry had triggered concerns about misuse and confusion among prescribers as costs fall sharply.
The Central Drugs Standard Control Organization (CDSCO) conducted inspections at 49 entities across the country, including drug wholesalers, retailers, and slimming clinics, the statement said.
It focused on identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing, the statement said, adding that notices were sent to defaulting entities.
"These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks," the statement said, adding that there have been concerns regarding their on-demand availability across various platforms.
Earlier this month, the CDSCO also warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promotions.
Analysts had expected more than 40 Indian drugmakers to launch over 50 brands after patent expiry, as they race to grab a share of the market that could grow to 80 billion rupees ($852.62 million) by 2030 from about 15 billion rupees today, according to research firm Pharmarack.
($1 = 93.8280 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad and Urvi Dugar in Bengaluru; Editing by Rashmi Aich and Janane Venkatraman)
Adds background, details from statement
March 24 (Reuters) - India's drug regulator has tightened surveillance against the unauthorised sale and promotion of weight-loss drugs, the health ministry said on Tuesday, after local drugmakers launched cheaper generic versions of Ozempic and Wegovy over the weekend.
At least half a dozen Indian drugmakers, including Dr Reddy's REDY.NS, Zydus ZYDU.NS and Sun Pharma SUN.NS, launched multiple brands of the blockbuster diabetes and weight-loss drugs, up to 70% cheaper than Novo Nordisk's drugs in some cases, after the patent for semaglutide expired last week.
Semaglutide is the active component in Ozempic and Wegovy.
The patent expiry had triggered concerns about misuse and confusion among prescribers as costs fall sharply.
The Central Drugs Standard Control Organization (CDSCO) conducted inspections at 49 entities across the country, including drug wholesalers, retailers, and slimming clinics, the statement said.
It focused on identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing, the statement said, adding that notices were sent to defaulting entities.
"These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks," the statement said, adding that there have been concerns regarding their on-demand availability across various platforms.
Earlier this month, the CDSCO also warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promotions.
Analysts had expected more than 40 Indian drugmakers to launch over 50 brands after patent expiry, as they race to grab a share of the market that could grow to 80 billion rupees ($852.62 million) by 2030 from about 15 billion rupees today, according to research firm Pharmarack.
($1 = 93.8280 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad and Urvi Dugar in Bengaluru; Editing by Rashmi Aich and Janane Venkatraman)
Zydus Lifesciences Launches Semaglutide Injection In Reusable Multi-Dose Pen Device In India, Priced At 2,200 Rupees Per Month
March 20 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - LAUNCHES SEMAGLUTIDE INJECTION IN REUSABLE MULTI-DOSE PEN DEVICE IN INDIA
ZYDUS LIFESCIENCES - HAS EXCLUSIVE RIGHTS TO REUSABLE PEN DEVICE FOR SEMAGLUTIDE
ZYDUS LIFESCIENCES - SEMAGLUTIDE INJECTION PRICED AT 2,200 RUPEES PER MONTH
ZYDUS LIFESCIENCES - ZYDUS' SEMAGLUTIDE INJECTION WILL BE AVAILABLE IN 15MG/3ML CARTRIDGE
ZYDUS LIFESCIENCES - SEMAGLUTIDE LAUNCHED UNDER SEMAGLYN, MASHEMA, AND ALTERME BRANDS
Source text: ID:nBSE3zPPz6
Further company coverage: ZYDU.NS
(([email protected];))
March 20 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - LAUNCHES SEMAGLUTIDE INJECTION IN REUSABLE MULTI-DOSE PEN DEVICE IN INDIA
ZYDUS LIFESCIENCES - HAS EXCLUSIVE RIGHTS TO REUSABLE PEN DEVICE FOR SEMAGLUTIDE
ZYDUS LIFESCIENCES - SEMAGLUTIDE INJECTION PRICED AT 2,200 RUPEES PER MONTH
ZYDUS LIFESCIENCES - ZYDUS' SEMAGLUTIDE INJECTION WILL BE AVAILABLE IN 15MG/3ML CARTRIDGE
ZYDUS LIFESCIENCES - SEMAGLUTIDE LAUNCHED UNDER SEMAGLYN, MASHEMA, AND ALTERME BRANDS
Source text: ID:nBSE3zPPz6
Further company coverage: ZYDU.NS
(([email protected];))
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
Novo Nordisk's India patent on semaglutide expires this week
Move to trigger wave of cheaper generics from local drugmakers
Concerns raised about misuse, uneven oversight
By Rishika Sadam
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's NOVOb.CO patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, but also raising concerns about misuse and confusion among prescribers as costs fall sharply.
Sun Pharma SUN.NS, Mankind Pharma MNKI.NS, Dr. Reddy's REDY.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Alkem ALKE.NS are among the companies expected to launch generic versions of semaglutide, the active ingredient in Novo's diabetes drug Ozempic and weight-loss treatment Wegovy.
"With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets," said Salil Kallianpur, an independent analyst.
"This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening."
India's drug regulator did not respond to a request for comment. Semaglutide is a prescription drug, but enforcement in India has often been uneven, with doctors and pharmacists playing a key gatekeeping role.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of launch, according to data from Pharmarack, a research firm.
India, the world's most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet, a medical journal, and the International Diabetes Federation.
India's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030 from about 15 billion rupees today, according to Pharmarack estimates.
EYES ON THE PRICE
Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.
Analysts say monthly prices for the lowest dose could fall from about 11,000 rupees to 3,000 to 5,000 rupees as early generics arrive and eventually to around 1,500 to 2,500 rupees, expanding access beyond a niche urban elite.
"I will consult my doctor to check if I can move to using a generic version, as that appears to be lighter on the pocket," said 32-year-old Vishal, a tech worker from Hyderabad, who is considering a switch from Wegovy.
Many other patients in India's out-of-pocket market have also begun enquiring about cheaper options, some of which are expected to launch as soon as Saturday, the day after Novo's patent expires.
"The price range being quoted is broadly 2,500 to 3,500 rupees, which is quite low," said bariatric surgeon Venugopal Pareek. Six of his patients are waiting for generic versions to switch from Novo or Lilly drugs.
Lower prices are expected to expand the patient pool.
"Onboarding of patients from lower economic strata may happen on branded generics," said Sheetal Sapale, commercial vice president at Pharmarack, noting that company profits would depend on pricing discipline.
Novo and Lilly did not immediately respond to Reuters requests for a comment.
DOCTORS' CHOICE
Even as prices fall, analysts say the winner in the market will depend not just on cost, but also on doctor confidence.
India's pharmaceutical market is heavily driven by physician prescriptions and uptake will depend on doctors' familiarity and confidence in individual brands.
An initial glut of products is likely to overwhelm prescribers, analysts said, with uneven experiences and aggressive marketing.
Many generic drugmakers are opting for brand names that incorporate "sema," which could also add to confusion.
Over time, analysts expect doctors' trust to consolidate around a handful of players offering reliable supply, quality delivery devices and consistent outcomes.
"Weaker players with poor quality and no differentiation will likely exit within two to three years," Kallianpur said.
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Thomas Derpinghaus)
(([email protected];))
Novo Nordisk's India patent on semaglutide expires this week
Move to trigger wave of cheaper generics from local drugmakers
Concerns raised about misuse, uneven oversight
By Rishika Sadam
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's NOVOb.CO patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, but also raising concerns about misuse and confusion among prescribers as costs fall sharply.
Sun Pharma SUN.NS, Mankind Pharma MNKI.NS, Dr. Reddy's REDY.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Alkem ALKE.NS are among the companies expected to launch generic versions of semaglutide, the active ingredient in Novo's diabetes drug Ozempic and weight-loss treatment Wegovy.
"With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets," said Salil Kallianpur, an independent analyst.
"This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening."
India's drug regulator did not respond to a request for comment. Semaglutide is a prescription drug, but enforcement in India has often been uneven, with doctors and pharmacists playing a key gatekeeping role.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of launch, according to data from Pharmarack, a research firm.
India, the world's most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet, a medical journal, and the International Diabetes Federation.
India's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030 from about 15 billion rupees today, according to Pharmarack estimates.
EYES ON THE PRICE
Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.
Analysts say monthly prices for the lowest dose could fall from about 11,000 rupees to 3,000 to 5,000 rupees as early generics arrive and eventually to around 1,500 to 2,500 rupees, expanding access beyond a niche urban elite.
"I will consult my doctor to check if I can move to using a generic version, as that appears to be lighter on the pocket," said 32-year-old Vishal, a tech worker from Hyderabad, who is considering a switch from Wegovy.
Many other patients in India's out-of-pocket market have also begun enquiring about cheaper options, some of which are expected to launch as soon as Saturday, the day after Novo's patent expires.
"The price range being quoted is broadly 2,500 to 3,500 rupees, which is quite low," said bariatric surgeon Venugopal Pareek. Six of his patients are waiting for generic versions to switch from Novo or Lilly drugs.
Lower prices are expected to expand the patient pool.
"Onboarding of patients from lower economic strata may happen on branded generics," said Sheetal Sapale, commercial vice president at Pharmarack, noting that company profits would depend on pricing discipline.
Novo and Lilly did not immediately respond to Reuters requests for a comment.
DOCTORS' CHOICE
Even as prices fall, analysts say the winner in the market will depend not just on cost, but also on doctor confidence.
India's pharmaceutical market is heavily driven by physician prescriptions and uptake will depend on doctors' familiarity and confidence in individual brands.
An initial glut of products is likely to overwhelm prescribers, analysts said, with uneven experiences and aggressive marketing.
Many generic drugmakers are opting for brand names that incorporate "sema," which could also add to confusion.
Over time, analysts expect doctors' trust to consolidate around a handful of players offering reliable supply, quality delivery devices and consistent outcomes.
"Weaker players with poor quality and no differentiation will likely exit within two to three years," Kallianpur said.
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Thomas Derpinghaus)
(([email protected];))
Zydus Lifesciences And Lupin Sign Licensing Agreement For Co-Marketing Innovative Semaglutide Injection In India
March 17 (Reuters) - Lupin Ltd LUPN.NS:
CO AND LUPIN SIGN LICENSING AGREEMENT FOR CO-MARKETING INNOVATIVE SEMAGLUTIDE INJECTION IN INDIA
Further company coverage: LUPN.NS
(([email protected];;))
March 17 (Reuters) - Lupin Ltd LUPN.NS:
CO AND LUPIN SIGN LICENSING AGREEMENT FOR CO-MARKETING INNOVATIVE SEMAGLUTIDE INJECTION IN INDIA
Further company coverage: LUPN.NS
(([email protected];;))
Zydus Lifesciences Says Sentynl Therapeutics Enters Into Agreement With PRG S&T
March 16 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - SENTYNL THERAPEUTICS ENTERS INTO AGREEMENT WITH PRG S&T
ZYDUS LIFESCIENCES - AGREEMENT TO LICENSE MOLECULE FOR HUTCHINSONGILFORD PROGERIA SYNDROME
Further company coverage: ZYDU.NS
(([email protected];))
March 16 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - SENTYNL THERAPEUTICS ENTERS INTO AGREEMENT WITH PRG S&T
ZYDUS LIFESCIENCES - AGREEMENT TO LICENSE MOLECULE FOR HUTCHINSONGILFORD PROGERIA SYNDROME
Further company coverage: ZYDU.NS
(([email protected];))
Zydus Lifesciences Receives Final Approval From USFDA For Cevimeline Hydrochloride Capsules 30Mg
March 13 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES FINAL APPROVAL FROM USFDA FOR CEVIMELINE HYDROCHLORIDE CAPSULES 30MG
Source text: [ID:]
Further company coverage: ZYDU.NS
(([email protected];))
March 13 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
RECEIVES FINAL APPROVAL FROM USFDA FOR CEVIMELINE HYDROCHLORIDE CAPSULES 30MG
Source text: [ID:]
Further company coverage: ZYDU.NS
(([email protected];))
Agenus triggers first USD 20 million contingent payment under Zydus collaboration for BOT and BAL production orders
Agenus said it triggered a USD 20 million contingent payment under its collaboration with Zydus after contracted work orders were placed for CMC and production activities for botensilimab and balstilimab. The work orders cover manufacturing to support BLA and MAA readiness and to initiate Zydus’ commercial supply activities for the programs. Agenus added that up to USD 50 million in contingent payments may be triggered under the agreement by future BOT and BAL production orders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260310252290) on March 10, 2026, and is solely responsible for the information contained therein.
Agenus said it triggered a USD 20 million contingent payment under its collaboration with Zydus after contracted work orders were placed for CMC and production activities for botensilimab and balstilimab. The work orders cover manufacturing to support BLA and MAA readiness and to initiate Zydus’ commercial supply activities for the programs. Agenus added that up to USD 50 million in contingent payments may be triggered under the agreement by future BOT and BAL production orders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260310252290) on March 10, 2026, and is solely responsible for the information contained therein.
Zydus Lifesciences Says Successful Clinical Development Of Pembrolizumab Biosimilar Fyb206
Feb 27 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - SUCCESSFUL CLINICAL DEVELOPMENT OF PEMBROLIZUMAB BIOSIMILAR FYB206
ZYDUS LIFESCIENCES - ACHIEVEMENT CLEARS PATHWAY FOR NEAR-TERM BLA FILING WITH USFDA
Further company coverage: ZYDU.NS
(([email protected];))
Feb 27 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - SUCCESSFUL CLINICAL DEVELOPMENT OF PEMBROLIZUMAB BIOSIMILAR FYB206
ZYDUS LIFESCIENCES - ACHIEVEMENT CLEARS PATHWAY FOR NEAR-TERM BLA FILING WITH USFDA
Further company coverage: ZYDU.NS
(([email protected];))
Zydus Lifesciences Plans To Launch Innovative Semaglutide Injection In India On Day 1 Of Patent Expiry
Feb 25 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS PLANS TO LAUNCH INNOVATIVE SEMAGLUTIDE INJECTION IN INDIA ON DAY 1 OF PATENT EXPIRY
Source text: [ID:]
Further company coverage: ZYDU.NS
(([email protected];;))
Feb 25 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS PLANS TO LAUNCH INNOVATIVE SEMAGLUTIDE INJECTION IN INDIA ON DAY 1 OF PATENT EXPIRY
Source text: [ID:]
Further company coverage: ZYDU.NS
(([email protected];;))
Zydus Lifesciences Launches Biosimilar Aflibercept 2 Mg Anyra
Feb 19 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
LAUNCHES BIOSIMILAR AFLIBERCEPT 2 MG ANYRA
SIGNS AGREEMENT WITH REGENERON AND BAYER
Source text: ID:nBSE88q1Wr
Further company coverage: ZYDU.NS
(([email protected];;))
Feb 19 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
LAUNCHES BIOSIMILAR AFLIBERCEPT 2 MG ANYRA
SIGNS AGREEMENT WITH REGENERON AND BAYER
Source text: ID:nBSE88q1Wr
Further company coverage: ZYDU.NS
(([email protected];;))
Zydus Lifesciences Receives US FDA Approval For Bosentan Tablets, 32 Mg
Feb 18 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - RECEIVES USFDA APPROVAL FOR BOSENTAN TABLETS, 32 MG
Source text: ID:nNSEv1bc5
Further company coverage: ZYDU.NS
(([email protected];;))
Feb 18 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - RECEIVES USFDA APPROVAL FOR BOSENTAN TABLETS, 32 MG
Source text: ID:nNSEv1bc5
Further company coverage: ZYDU.NS
(([email protected];;))
India's Zydus Life agrees $120 million settlement with Astellas over bladder drug
Adds stock prices in paragraph 4
Feb 12 (Reuters) - India's Zydus Lifesciences ZYDU.NS and its U.S. unit will pay $120 million to Astellas Pharma 4503.T as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron, the Indian firm said on Thursday.
Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the U.S. from the date of the agreement until September 2027, the company said.
The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions of the agreement are confidential.
Shares of Zydus climbed as much as 1.3% shortly after the announcement.
The announcement comes days after local peer Lupin LUPN.NS decided to settle its dispute with Astellas over the same drug for $90 million.
At that time, analysts at brokerage Citi said the development could delay the entry of other generic rivals in the U.S. market, potentially providing Zydus and Lupin with a period of limited competition.
(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sherry Jacob-Phillips)
((mailto: [email protected]; @MukherjeeHritam;))
Adds stock prices in paragraph 4
Feb 12 (Reuters) - India's Zydus Lifesciences ZYDU.NS and its U.S. unit will pay $120 million to Astellas Pharma 4503.T as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron, the Indian firm said on Thursday.
Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the U.S. from the date of the agreement until September 2027, the company said.
The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions of the agreement are confidential.
Shares of Zydus climbed as much as 1.3% shortly after the announcement.
The announcement comes days after local peer Lupin LUPN.NS decided to settle its dispute with Astellas over the same drug for $90 million.
At that time, analysts at brokerage Citi said the development could delay the entry of other generic rivals in the U.S. market, potentially providing Zydus and Lupin with a period of limited competition.
(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sherry Jacob-Phillips)
((mailto: [email protected]; @MukherjeeHritam;))
Zydus Lifesciences Q3 Consol Net Profit 10.42 Billion Rupees
Feb 9 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES Q3 CONSOL NET PROFIT 10.42 BILLION RUPEES; IBES EST. 9.32 BILLION RUPEES
ZYDUS LIFESCIENCES Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 68.65 BILLION RUPEES; IBES EST. 61.76 BILLION RUPEES
Source text: ID:nBSE2fz8FD
Further company coverage: ZYDU.NS
(([email protected];;))
Feb 9 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES Q3 CONSOL NET PROFIT 10.42 BILLION RUPEES; IBES EST. 9.32 BILLION RUPEES
ZYDUS LIFESCIENCES Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 68.65 BILLION RUPEES; IBES EST. 61.76 BILLION RUPEES
Source text: ID:nBSE2fz8FD
Further company coverage: ZYDU.NS
(([email protected];;))
Zydus Lifesciences Receives Tentative Approval From USFDA For Dapagliflozin Tablets
Feb 4 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DAPAGLIFLOZIN TABLETS
ZYDUS LIFESCIENCES - RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG
Source text: [ID:]
Further company coverage: ZYDU.NS
(([email protected];))
Feb 4 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DAPAGLIFLOZIN TABLETS
ZYDUS LIFESCIENCES - RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG
Source text: [ID:]
Further company coverage: ZYDU.NS
(([email protected];))
Zydus Lifesciences Says USFDA Inspection Closed With 2 Observations For Ankleshwar Unit-2 Plant
Jan 23 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
USFDA INSPECTION CLOSED AT ZYDUS UNIT-2 PLANT IN ANKLESHWAR
INSPECTION CONCLUDED WITH 3 OBSERVATIONS
Source text: ID:nBSE42WxM
Further company coverage: ZYDU.NS
(([email protected];))
Jan 23 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
USFDA INSPECTION CLOSED AT ZYDUS UNIT-2 PLANT IN ANKLESHWAR
INSPECTION CONCLUDED WITH 3 OBSERVATIONS
Source text: ID:nBSE42WxM
Further company coverage: ZYDU.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Split
Dividend
Dividend
More Mid Cap Ideas
See similar 'Mid' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Zydus Lifesciences do?
Zydus Lifesciences is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. The Company is committed to deliver high quality, affordable medicines to the patients by leveraging the best contemporary technology and process improvements.
Who are the competitors of Zydus Lifesciences?
Zydus Lifesciences major competitors are Mankind Pharma, Lupin, Dr. Reddy's Lab, Cipla, Aurobindo Pharma, Glenmark Pharma, Alkem Laboratories. Market Cap of Zydus Lifesciences is ₹1,01,755 Crs. While the median market cap of its peers are ₹1,03,011 Crs.
Is Zydus Lifesciences financially stable compared to its competitors?
Zydus Lifesciences seems to be less financially stable compared to its competitors. Altman Z score of Zydus Lifesciences is 7.91 and is ranked 4 out of its 8 competitors.
Does Zydus Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Zydus Lifesciences latest dividend payout ratio is 24.45% and 3yr average dividend payout ratio is 21.08%
How has Zydus Lifesciences allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Zydus Lifesciences balance sheet?
Balance sheet of Zydus Lifesciences is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Zydus Lifesciences improving?
Yes, profit is increasing. The profit of Zydus Lifesciences is ₹4,934 Crs for TTM, ₹4,526 Crs for Mar 2025 and ₹3,860 Crs for Mar 2024.
Is the debt of Zydus Lifesciences increasing or decreasing?
Yes, The net debt of Zydus Lifesciences is increasing. Latest net debt of Zydus Lifesciences is ₹6,811 Crs as of Sep-25. This is greater than Mar-25 when it was -₹2,743.5 Crs.
Is Zydus Lifesciences stock expensive?
Zydus Lifesciences is not expensive. Latest PE of Zydus Lifesciences is 20.2, while 3 year average PE is 20.45. Also latest EV/EBITDA of Zydus Lifesciences is 14.07 while 3yr average is 14.91.
Has the share price of Zydus Lifesciences grown faster than its competition?
Zydus Lifesciences has given better returns compared to its competitors. Zydus Lifesciences has grown at ~21.96% over the last 3yrs while peers have grown at a median rate of 20.24%
Is the promoter bullish about Zydus Lifesciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Zydus Lifesciences is 75.0% and last quarter promoter holding is 75.0%.
Are mutual funds buying/selling Zydus Lifesciences?
The mutual fund holding of Zydus Lifesciences is increasing. The current mutual fund holding in Zydus Lifesciences is 4.88% while previous quarter holding is 4.71%.